Prudential Financial Inc Arbutus Biopharma Corp Transaction History

Prudential Financial Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.52 - $3.63 $6,022 - $8,675	2,390 Added 18.99%	14,975 $46,000
Q4 2023 Feb 13, 2024	BUY	$1.69 - $2.54 $2,061 - $3,098	1,220 Added 10.73%	12,585 $31,000
Q1 2023 May 12, 2023	SELL	$2.23 - $3.1 $182,637 - $253,890	-81,900 Reduced 87.81%	11,365 $34,000
Q4 2022 Feb 14, 2023	BUY	$1.91 - $2.85 $112,499 - $167,865	58,900 Added 171.4%	93,265 $0
Q3 2022 Nov 04, 2022	BUY	$1.88 - $2.88 $235 - $360	125 Added 0.37%	34,365 $65,000
Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $836,391 - $1.34 Million	-422,420 Reduced 92.5%	34,240 $93,000
Q1 2022 May 13, 2022	BUY	$2.42 - $3.98 $124,146 - $204,174	51,300 Added 12.66%	456,660 $1.36 Million
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $1.26 Million - $1.87 Million	405,360 New	405,360 $1.58 Million

155

99.5M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $478M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.